Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioAge Labs, Inc.BIOA · Entity 5569 | Principal Accounting Officer | June 29, 2026 | July 01, 2026 |
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | VP & Corporate Controller | June 07, 2023 | June 09, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioAge Labs, Inc.
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-06-30 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2026-06-29 · Exercise / conversion · Acquired 9,301 · Balance 11,933 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Row 2 · 2026-06-29 · Exercise / conversion · Acquired 7,261 · Balance 19,194 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Row 3 · 2026-06-29 · Exercise / conversion · Acquired 8,958 · Balance 28,152 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Row 4 · 2026-06-29 · Exercise / conversion · Acquired 14,198 · Balance 42,350 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Row 5 · 2026-06-29 · Sale · Disposed 42,350 · Balance 0 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Row 6 · 2026-06-30 · Exercise / conversion · Acquired 4,290 · Balance 4,290 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Row 7 · 2026-06-30 · Exercise / conversion · Acquired 4,000 · Balance 8,290 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Row 8 · 2026-06-30 · Exercise / conversion · Acquired 4,065 · Balance 12,355 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Row 9 · 2026-06-30 · Exercise / conversion · Acquired 7,861 · Balance 20,216 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Row 10 · 2026-06-30 · Sale · Disposed 20,216 · Balance 0 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.85 · Expires 2033-09-26 | Direct | 17,589 |
Reported balance
After 2026-06-29 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-06-29 · Exercise / conversion · Disposed 9,301 · Balance 17,589 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F4: The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.39 · Expires 2034-04-16 | Direct | 21,016 |
Reported balance
After 2026-06-29 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-06-29 · Exercise / conversion · Disposed 7,261 · Balance 21,016 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F5: The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2034-12-17 | Direct | 31,042 |
Reported balance
After 2026-06-29 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-06-29 · Exercise / conversion · Disposed 8,958 · Balance 31,042 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F6: The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.38 · Expires 2035-02-17 | Direct | 75,802 |
Reported balance
After 2026-06-29 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-06-29 · Exercise / conversion · Disposed 14,198 · Balance 75,802 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F7: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.85 · Expires 2033-09-26 | Direct | 13,299 |
Reported balance
After 2026-06-30 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-06-30 · Exercise / conversion · Disposed 4,290 · Balance 13,299 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F4: The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.39 · Expires 2034-04-16 | Direct | 17,016 |
Reported balance
After 2026-06-30 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-06-30 · Exercise / conversion · Disposed 4,000 · Balance 17,016 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F5: The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2034-12-17 | Direct | 26,977 |
Reported balance
After 2026-06-30 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-06-30 · Exercise / conversion · Disposed 4,065 · Balance 26,977 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F6: The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.38 · Expires 2035-02-17 | Direct | 67,941 |
Reported balance
After 2026-06-30 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-06-30 · Exercise / conversion · Disposed 7,861 · Balance 67,941 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F7: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive.
F4: The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F5: The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F6: The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F7: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
PRECISION BIOSCIENCES INC
Report date June 07, 2023 · Filed June 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,502 |
Reported balance
After 2023-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-07 · Exercise / conversion · Acquired 6,060 · Balance 27,502 F1: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2023. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. F3: Amount includes 20 shares that were inadvertently omitted from the Form 4 filed on March 7, 2023 by the Reporting Person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,060 |
Reported balance
After 2023-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-07 · Exercise / conversion · Disposed 6,060 · Balance 6,060 F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. F4: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2023.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share.
F3: Amount includes 20 shares that were inadvertently omitted from the Form 4 filed on March 7, 2023 by the Reporting Person.
F4: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,861 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · derivative · entry 18 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,941 Underlying: Common Stock · 7,861 shares Expires 2035-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F7 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,065 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · derivative · entry 17 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,977 Underlying: Common Stock · 4,065 shares Expires 2034-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F6 · derivative.exercise_date: The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · derivative · entry 16 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,016 Underlying: Common Stock · 4,000 shares Expires 2034-04-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F5 · derivative.exercise_date: The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,290 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · derivative · entry 15 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,299 Underlying: Common Stock · 4,290 shares Expires 2033-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F4 · derivative.exercise_date: The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 20,216 | $25.19 | $509,176.35 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · nonDerivative · entry 10 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 7,861 | $4.38 | $34,431.18 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · nonDerivative · entry 9 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 4,065 | $4.30 | $17,479.50 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · nonDerivative · entry 8 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 4,000 | $8.39 | $33,560.00 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · nonDerivative · entry 7 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 4,290 | $10.85 | $46,546.50 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · nonDerivative · entry 6 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,198 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · derivative · entry 14 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,802 Underlying: Common Stock · 14,198 shares Expires 2035-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F7 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,958 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · derivative · entry 13 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,042 Underlying: Common Stock · 8,958 shares Expires 2034-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F6 · derivative.exercise_date: The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,261 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · derivative · entry 12 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,016 Underlying: Common Stock · 7,261 shares Expires 2034-04-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F5 · derivative.exercise_date: The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,301 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · derivative · entry 11 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,589 Underlying: Common Stock · 9,301 shares Expires 2033-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F4 · derivative.exercise_date: The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | SaleCommon Stock | 42,350 | $25.21 | $1,067,575.74 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · nonDerivative · entry 5 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 14,198 | $4.38 | $62,187.24 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · nonDerivative · entry 4 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 8,958 | $4.30 | $38,519.40 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · nonDerivative · entry 3 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 7,261 | $8.39 | $60,919.79 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · nonDerivative · entry 2 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 20:27 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | Exercise / conversionCommon Stock | 9,301 | $10.85 | $100,915.85 |
DisclosureSEC source: 0001836297-26-000005 · form4-07012026_080701.xml · nonDerivative · entry 1 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,933 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $19.63 | $0.00 |
DisclosureSEC source: 0001836297-26-000002 · form4-02192026_090243.xml · derivative · entry 1 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:15 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $4.38 | $0.00 |
DisclosureSEC source: 0001415889-25-004854 · form4-02202025_090229.xml · derivative · entry 1 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 21:04 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001415889-24-029962 · form4-12202024_091252.xml · derivative · entry 1 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-12-17 F1 · derivative.exercise_date: The option shall vest as to 1/48th of the total award monthly, with the first tranche vesting on October 26, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| September 27, 2024 Filed Mar 10, 2025 20:10 UTC | BioAge Labs, Inc. BIOA · Entity 5569 | PurchaseCommon Stock | 2,632 | $18.00 | $47,376.00 |
DisclosureSEC source: 0001415889-25-007505 · form4-03102025_080333.xml · nonDerivative · entry 1 Barton Shane · CIK 0001836297 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,632 F1 · shares: The reported securities were purchased through a directed share program in connection with the Issuer's initial public offering. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:20 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 6,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-035835 · doc4.xml · derivative · entry 2 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,060 Underlying: Common Stock · 6,060 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. F4 · derivative.exercise_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F4 · derivative.expiration_date: On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:20 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 6,060 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-035835 · doc4.xml · nonDerivative · entry 1 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2023. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock or, at the Issuer's option, an amount of cash equal to the fair market value of such share. F3 · balance_after: Amount includes 20 shares that were inadvertently omitted from the Form 4 filed on March 7, 2023 by the Reporting Person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 22:04 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 12,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016824 · doc4.xml · derivative · entry 2 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,439 Underlying: Common Stock · 12,722 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F3 · derivative.expiration_date: On March 3, 2022 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on March 3, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 22:04 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 12,722 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016824 · doc4.xml · nonDerivative · entry 1 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on March 3, 2023. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004609 · doc4.xml · derivative · entry 1 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award vests in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award vests in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:26 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 6,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035391 · doc4.xml · derivative · entry 2 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,120 Underlying: Common Stock · 6,061 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: On June 7, 2021 the Reporting person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F3 · derivative.expiration_date: On June 7, 2021 the Reporting person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:26 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 6,061 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-035391 · doc4.xml · nonDerivative · entry 1 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2022. F2 · price: Each RSU represents a contingent right to receive one share of the Company's Common Stock. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:22 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 38,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016641 · doc4.xml · derivative · entry 5 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,161 Underlying: Common Stock · 38,161 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F3 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:22 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,604 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001209191-22-016641 · doc4.xml · derivative · entry 4 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,604 Underlying: Common Stock · 60,604 shares Expires 2032-03-02 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on March 3, 2023 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| February 28, 2022 Filed Mar 7, 2022 21:22 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 761 | $3.61 | $2,747.21 |
DisclosureSEC source: 0001209191-22-016641 · doc4.xml · nonDerivative · entry 3 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,659 Read SEC document |
| August 31, 2021 Filed Mar 7, 2022 21:22 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 604 | $10.68 | $6,450.72 |
DisclosureSEC source: 0001209191-22-016641 · doc4.xml · nonDerivative · entry 2 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,898 Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:35 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 18,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039276 · doc4.xml · derivative · entry 2 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,181 Underlying: Common Stock · 18,181 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F3 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:35 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 31,242 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039276 · doc4.xml · derivative · entry 1 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,242 Underlying: Common Stock · 31,242 shares Expires 2031-06-06 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Read SEC document |
| February 26, 2021 Filed Mar 7, 2022 21:22 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 1,294 | $4.61 | $5,965.34 |
DisclosureSEC source: 0001209191-22-016641 · doc4.xml · nonDerivative · entry 1 Barton Shane · CIK 0001836297 · VP & Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,294 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.